Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran University of Medical Science, Tehran.
Endocrine Research Center, Tabriz University of Medical Sciences, Tabriz.
Eur J Gastroenterol Hepatol. 2022 Mar 1;34(3):345-353. doi: 10.1097/MEG.0000000000002323.
Although several experimental models have suggested promising pharmacological effects of naringenin in the management of obesity and its related disorders, the effects of naringenin supplementation on cardiovascular disorders as one of the main complications of nonalcoholic fatty liver disease (NAFLD) are yet to be examined in humans.
In this double-blind, placebo-controlled, randomized clinical trial, 44 overweight/obese patients with NAFLD were equally allocated into either naringenin or placebo group for 4 weeks. Cardiovascular risk factors including atherogenic factors, hematological indices, obesity-related parameters, blood pressure, and heart rate were assessed pre- and postintervention.
The atherogenic index of plasma value, serum non-HDL-C levels as well as total cholesterol/high-density lipoprotein cholesterol (HDL-C), triglyceride/HDL-C, low-density lipoprotein cholesterol/HDL-C, and non-HDL-C/HDL-C ratios were significantly reduced in the intervention group, compared to the placebo group post intervention (P < 0.05). Moreover, there was a significant reduction in BMI and visceral fat level in the intervention group when compared with the placebo group (P = 0.001 and P = 0.039, respectively). Furthermore, naringenin supplementation could marginally reduce systolic blood pressure (P = 0.055). Mean corpuscular hemoglobin increased significantly in the naringenin group compared to the placebo group at the endpoint (P = 0.023). Supplementation with naringenin also resulted in a marginally significant increase in the mean corpuscular hemoglobin concentration when compared with the placebo group (P = 0.050). There were no significant between-group differences for other study outcomes post intervention.
In conclusion, these data indicate that naringenin supplementation may be a promising treatment strategy for cardiovascular complications among NAFLD patients. However, further trials are warranted.
尽管有几项实验模型表明柚皮素在肥胖及其相关疾病的治疗中有很好的药理作用，但柚皮素补充剂对心血管疾病的影响（非酒精性脂肪肝疾病 [NAFLD] 的主要并发症之一）尚未在人类中得到检验。
在这项双盲、安慰剂对照、随机临床试验中，将 44 名超重/肥胖的 NAFLD 患者等分为柚皮素组和安慰剂组，分别进行 4 周的治疗。在干预前后评估心血管危险因素，包括致动脉粥样硬化因素、血液学指标、肥胖相关参数、血压和心率。
与安慰剂组相比，干预组的血浆致动脉粥样硬化指数、非高密度脂蛋白胆固醇水平以及总胆固醇/高密度脂蛋白胆固醇、甘油三酯/高密度脂蛋白胆固醇、低密度脂蛋白胆固醇/高密度脂蛋白胆固醇和非高密度脂蛋白胆固醇/高密度脂蛋白胆固醇比值均显著降低（P<0.05）。此外，与安慰剂组相比，干预组的 BMI 和内脏脂肪水平显著降低（P=0.001 和 P=0.039）。此外，柚皮素补充剂可使收缩压略有降低（P=0.055）。与安慰剂组相比，柚皮素组在终点时平均红细胞血红蛋白显著增加（P=0.023）。与安慰剂组相比，柚皮素组的平均红细胞血红蛋白浓度也略有显著增加（P=0.050）。干预后，其他研究结果两组间无显著差异。
总之，这些数据表明，柚皮素补充剂可能是治疗 NAFLD 患者心血管并发症的一种有前途的治疗策略。然而，还需要进一步的试验。
